Skip to content
← Full study record

NCT00886769 · OUTCOME

Change in Health-related Quality of Life (HRQoL)Over Time by Use of the Child Health Questionnaire - Parent Form (CHQ-PF50)

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) · Source last updated 2017-03-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
LEAST_SQUARES_MEAN
Unit
units on a scale
Interval / dispersion
Standard Error
Time frame
Over 4 week study period (Baseline, Day 15, Day 29)

What was measured

CHQ-PF50 measures HRQoL in children 5-18 years old from parent's perspective. Questionnaire completed by parent without input from patient. Total score ranges from 0-100. Increases in scores represent improved well-being in subjects as assessed by their parents. Mixed linear model on change from baseline in CHQ-PF50 score with treatment group, stratification factors, day of assessment and interaction between group and day as covariates. Covariance analysis used a repeated measures approach, so all timepoints over time were taken into account.

Analysis population: The Full Analysis Set (FAS) consisted of all randomized patients who received at least one dose of study drug. Observed cases only were analyzed.

Groups in this outcome

Canakinumab

Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\>37.5 kg) received two sc injections.

Placebo

Patients received a single dose matching placebo of canakinumab on day 1.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Canakinumab28
Placebo34

Reported measurements

CHQ-PF50 physical score
Values in units on a scale · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Canakinumab16.93.46Not reportedNot reportedNot reported
Placebo4.93.97Not reportedNot reportedNot reported
CHQ-PF50 psychosocial score
Values in units on a scale · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Canakinumab6.22.15Not reportedNot reportedNot reported
Placebo-1.12.49Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        3.46
        value
        16.9
      2. group Id
        OG001
        spread
        3.97
        value
        4.9
    title
    CHQ-PF50 physical score
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        2.15
        value
        6.2
      2. group Id
        OG001
        spread
        2.49
        value
        -1.1
    title
    CHQ-PF50 psychosocial score
denoms
  1. counts
    1. group Id
      OG000
      value
      28
    2. group Id
      OG001
      value
      34
    units
    Participants
description
CHQ-PF50 measures HRQoL in children 5-18 years old from parent's perspective. Questionnaire completed by parent without input from patient. Total score ranges from 0-100. Increases in scores represent improved well-being in subjects as assessed by their parents. Mixed linear model on change from baseline in CHQ-PF50 score with treatment group, stratification factors, day of assessment and interaction between group and day as covariates. Covariance analysis used a repeated measures approach, so all timepoints over time were taken into account.
dispersion Type
Standard Error
groups
  1. description
    Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\>37.5 kg) received two sc injections.
    id
    OG000
    title
    Canakinumab
  2. description
    Patients received a single dose matching placebo of canakinumab on day 1.
    id
    OG001
    title
    Placebo
param Type
LEAST_SQUARES_MEAN
population Description
The Full Analysis Set (FAS) consisted of all randomized patients who received at least one dose of study drug. Observed cases only were analyzed.
reporting Status
POSTED
time Frame
Over 4 week study period (Baseline, Day 15, Day 29)
title
Change in Health-related Quality of Life (HRQoL)Over Time by Use of the Child Health Questionnaire - Parent Form (CHQ-PF50)
type
SECONDARY
unit Of Measure
units on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice